Instruments

Elevating Glaucoma Care with Nocturnal IOP Control

Norbert Lowe

Norbert Lowe, CCO of Balance Ophthalmics

Final Medicare payment amounts for the FSYX OPAP and associated goggles took effect Oct. 1

Oct. 28, 2026

For optometrists managing open-angle glaucoma, achieving optimal long-term outcomes often means confronting a familiar puzzle: patients whose intraocular pressure (IOP) appears well-controlled during daytime office visits, yet whose OCT and visual field scans continue to show progressive optic nerve damage. For many of these patients, the missing link comes down to a combination of factors. But some of them are simple physics: body and head positions and gravity. When patients lie flat at night, nocturnal IOP spikes routinely undermine daytime clinical gains, explains Norbert Lowe, Chief Commercial Officer at Balance Ophthalmics.

To help optometrists protect their patients’ visual fields and halt potential hidden progression, Balance Ophthalmics developed the FSYX Ocular Pressure Adjusting Pump (OPAP) and associated goggles—a novel negative-pressure solution designed to stabilize nighttime pressure.

The science of negative pressure

The initial concept for the technology grew from an intuitive question posed by founder John Berdahl, MD, who wondered why scuba divers do not routinely suffer from elevated glaucoma risks despite the environmental pressure changes they experience.

fxys ocular pressure adjusting pump goggles - Nocturnal IOP Management

The FSYX Ocular Pressure Adjusting Pump (OPAP) and associated goggles

“If you press on your eye, your IOP goes up. Release that pressure, and it comes right back to baseline,” says Lowe. “When a patient lies flat at night, physics dictates an upward shift in fluid dynamics and intraocular pressure.”

Research from institutions such as UC San Diego, led by Robert Weinreb, MD, underscores the scope of the problem. Overnight sleep studies revealed that even patients whose daytime IOP remains stable around 16 mmHg experience nocturnal spikes averaging 2 to 6 mmHg per night. By programming the FSYX pump to apply a specific negative pressure, the system counteracts those nocturnal spikes while the patient sleeps. For example, a -10 mmHg setting achieves a 5 to 6 mmHg reduction.

Target patients and practice integration

The Fsyx device is strictly prescription-only and designed as an adjunct treatment rather than a monotherapy for patients needing better long-term outcomes.

“Our indication is for primary open-angle glaucoma patients with an IOP of 21 mmHg or lower who have already been treated,” Lowe says. “These are patients who are on drops or have had previous glaucoma surgical procedures, but their OCT and visual field scans show they are still progressing.”

When optometrists identify a progressing patient who needs an additional therapeutic line, they can submit a prescription and letter of medical necessity. Just this summer, the Centers for Medicare and Medicaid Services established final 2026 Medicare payment amounts for the FSYX device, with rates taking effect October 1.

Dedicated support and usage tracking

To ensure the technology integrates seamlessly without burdening practice staff, Balance Ophthalmics provides dedicated internal support, Lowe says.

“Each patient gets paired with an internal patient care counselor at Balance,” Lowe says. “That patient care counselor walks through the journey with them, so the patient isn’t having to call the doctor’s office back for basic troubleshooting.”

While the device does not monitor continuous IOP, it tracks daily usage and transmits usage data seamlessly via built-in 5G wireless technology. Eyecare professionals gain automated insights into patient compliance that they have never previously had access to, allowing them to verify whether the therapy is being used as intended prior to the standard three-month follow-up visit.

Unlocking a clinical need

In 52-week clinical evaluations, patient compliance with the negative-pressure system proved similar to or slightly higher compliance rates typically associated with daily glaucoma drops. Patient compliance with the FSYX device is generally high and consistent.

“There’s a significant body of data on nocturnal IOP spikes, but historically no one really addressed it because we didn’t have a solution,” Lowe says.

With positive reimbursement momentum, dedicated patient support and strong clinical feedback, the FSYX OPAP device offers optometrists a practical, physics-backed tool to potentially help slow glaucoma progression where daytime drops and surgical procedures reach their limit at nighttime.

On Oct. 1, final Medicare payment rates for the FSYX OPAP and associated goggles took effect. Read our coverage here.

Read more from The Aging Eye here.

Read more on instruments here.

To Top
Subscribe Today for Free...
And join more than 35,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.